ISSN 1674-3865  CN 21-1569/R
主管:国家卫生健康委员会
主办:中国医师协会
   辽宁省基础医学研究所
   辽宁中医药大学附属医院

中国中西医结合儿科学 ›› 2018, Vol. 10 ›› Issue (3): 216-219.doi: 10.3969/j.issn.1674-3865.2018.03.010

• 临床研究 • 上一篇    下一篇

孟鲁司特联合丹参酮治疗儿童过敏性紫癜的效果及对血清炎症因子的影响

李永水   

  1. 456750 河南 鹤壁,河南省淇县妇幼保健计划生育服务中心儿科
  • 出版日期:2018-06-25 上线日期:2018-11-19
  • 作者简介:李永水(1963-),男,副主任医师。研究方向:中西医结合治疗儿科免疫系统疾病,E-mail:liyongshuihb@163.com

Effect of montelukast combined with tanshinone on Henoch Schonlein purpura in children and its effect on serum inflammatory factors

LI Yongshui   

  1. Qi County Maternal and Child Health Planning and Child Care Service Center of Henan Province,Hebi 456750,China
  • Published:2018-06-25 Online:2018-11-19

摘要:
目的
分析孟鲁司特联合丹参酮治疗儿童过敏性紫癜的效果及对血清炎症因子的影响。
方法
选择2015年1月至2016年2月河南省淇县妇幼保健计划生育服务中心儿科收治的儿童过敏性紫癜患儿117例为研究对象,随机分为对照组58例和观察组59例。对照组采用孟鲁司特口服,观察组在对照组基础上联合应用丹参酮静脉滴注,30 d为1个疗程。观察两组患儿临床疗效、血清炎症因子(白细胞介素4、6及肿瘤坏死因子α)改善情况及不良反应发生率。
结果
观察组治疗后总有效率为96.6%(57/59),显著高于对照组82.8%(48/58),差异有统计学意义(P<0.05)。两组患儿治疗后白细胞介素4、6及肿瘤坏死因子α水平均较治疗前显著降低,差异具有统计学意义(P<0.05)。治疗30 d后,观察组白细胞介素4、6及肿瘤坏死因子α水平显著低于对照组,差异有统计学意义(P<0.05)。两组患儿治疗期间不良反应发生率比较差异无统计学意义(P>0.05)。
结论
孟鲁司特联合丹参酮能显著改善过敏性紫癜患儿的血清炎症因子水平,提高治疗疗效,安全性较佳。

关键词: 过敏性紫癜, 孟鲁司特, 丹参酮, 血清炎症因子, 儿童

Abstract:
Objective
To analyze the effect of montelukast combined with tanshinone on children with Henoch Schonlein purpura and its influence on serum inflammatory factors.
Methods
A total of 117 children with Henoch Schonlein purpura treated from January 2015 to February 2016 in Qi County Maternal and Child Health Planning and Child Care Service Center of Henan Province were selected as the study subjects, and they were randomly divided into the control group(58 cases) and observation group(59 cases). Both groups were treated with montelukast, and the observation group was given tanshinone intravenous drip, with 30 d as 1 course. The clinical efficacy, the improvement of serum inflammatory factors(interleukin 4, 6 and tumor necrosis factor alpha) and the incidence of adverse reactions were observed in both groups.
Results
The total effective rate of the observation group after treatment was 96.6%(57/59), which was significantly higher than that of the control group(82.8%,48/58), the difference being statistically significant(P<0.05). The levels of interleukin 4, 6 and TNF-alpha in both groups were significantly lower than those before treatment, and the difference was statistically significant(P<0.05). After treatment of 30d, the levels of interleukin 4, 6 and tumor necrosis factor alpha in the observation group were significantly lower than those in the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the 2 groups during the treatment period(P>0.05).
Conclusion
Montelukast combined with tanshinone can significantly improve the level of serum inflammatory factors in children with Henoch Schonlein purpura and the efficacy of treatment and it is safe.

Key words: Henoch Schonlein purpur, Montelukast, Tanshinone, Serum inflammatory factors, Children